Merck advances Winrevair in subset of heart failure patients
7.5
来源：
FiercePharma
发布时间：
2025-11-18 10:59
摘要：
Merck's Winrevair has shown positive results in a phase 2 trial for heart failure patients, specifically those with combined post- and precapillary pulmonary hypertension. The trial met its primary endpoint, indicating significant potential for this treatment. With no existing approved therapies for this subset of patients, Winrevair's advancement to phase 3 trials represents a critical step forward. The drug's commercial potential is underscored by projected sales reaching $6.2 billion by 2030, following its successful acquisition by Merck.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.0
technical_barrier_competition
0.0
关键证据
Winrevair improved the ability of blood to transition through the lungs to the heart.
The phase 2 Cadence trial met its primary endpoint.
Projected sales of the treatment to reach $6.2 billion by 2030.
真实性检查
否
AI评分总结
Merck's Winrevair has shown positive results in a phase 2 trial for heart failure patients, specifically those with combined post- and precapillary pulmonary hypertension. The trial met its primary endpoint, indicating significant potential for this treatment. With no existing approved therapies for this subset of patients, Winrevair's advancement to phase 3 trials represents a critical step forward. The drug's commercial potential is underscored by projected sales reaching $6.2 billion by 2030, following its successful acquisition by Merck.